Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

2015881 citationsJournal Articlehybrid Open Access

Authors

John C. Byrd · Dorset HealthCare University NHS Foundation Trust

Bonnie K. Harrington

Susan O’Brien · University of California, Irvine

Jeffrey A. Jones · The Ohio State University

Anna Schuh · University of Oxford

Stephen Devereux · King's College Hospital NHS Foundation Trust

Jorge Chaves · Northwest Medical Specialties

Abstract

In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Immunodeficiency and Autoimmune Disorders PI3K/AKT/mTOR signaling in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 374, Issue 4, pp. 323-332

DOI: 10.1056/nejmoa1509981

Field-Weighted Citation Impact: 47.41